There is a growing body of literature evaluating the use of biologic therapies such as Anakinra (IL‐1 antagonist), Emapalumab (interferon gamma antagonist), and Ruxolitinib (janus kinase inhibitor) in both primary and secondary HLH (infection, rheumatologic) due to their broad cytokine modulating abilities [23]. The gene discussed is IFNG; the disease is hemophagocytic syndrome.